IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
Healthcare
$26.17 -1.45%
-$0.45 today
- Market cap
- $2.53B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
52W Low $20.50High $39.28
Volume 1.42M
Average 1.44M
Income Statement
Follow revenue through to earnings.
Revenue
$218.71M
FY 2025 · Annual
+3024.4% YoYOperating Income
-$159.31M
FY 2025 · Annual
Net Income
-$113.70M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| 35.25M | 41.44M | 57.52M | 81.68M | 88.49M | |
| 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDYA Earnings Waterfall · TTM
NASDAQ:IDYA · Revenue to Net Income
Key Ratios
EPS$-1.60
Gross Margin-138.4%
Net Margin-552.6%
P/E Ratio-4.4
P/S Ratio186.0
Analysis
$225.3M of revenue converted into -$140.1M of net income for the selected period. Gross margin is -138.4% and net margin is -552.6%, showing how much revenue survives after costs and taxes. EPS is $-1.60, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
How much revenue does IDYA generate?
IDEAYA Biosciences, Inc. (IDYA) reported $218.71M of revenue in fiscal 2025.
Is IDYA profitable?
IDEAYA Biosciences, Inc. (IDYA) reported -$113.70M of net income, with a net margin of -52.0%.
Continue the stock analysis
Jump to another research area for this company.